The permeation of dynorphin A 1–6 across the blood brain barrier and its effect on bovine brain microvessel endothelial cell monolayer permeability
暂无分享,去创建一个
[1] S. Lunte,et al. Evaluation of an on-capillary copper complexation methodology for the investigation of in vitro metabolism of dynorphin A 1-17. , 2010, Journal of separation science.
[2] Allison T. Knoll,et al. Dynorphin, stress, and depression , 2010, Brain Research.
[3] V. Haroutunian,et al. Dysregulation of dynorphins in Alzheimer disease , 2007, Neurobiology of Aging.
[4] P. Andrén,et al. Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease. , 2005, Journal of mass spectrometry : JMS.
[5] Masaaki Iwata,et al. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant‐like effects , 2004, Journal of neurochemistry.
[6] B. Chait,et al. Dynorphin A(1–17) biotransformation in striatum of freely moving rats using microdialysis and matrix‐assisted laser desorption/ionization mass spectrometry , 2003, Journal of neurochemistry.
[7] D. Walker,et al. Site and mechanism of action of dynorphin A-(1-13) and N-methyl-D-aspartate on ACTH release in fetal sheep. , 2002, American journal of physiology. Endocrinology and metabolism.
[8] Jeffrey J. Jones,et al. MATRIX-ASSISTED LASER DESORPTION MASS SPECTROMETRY , 2002 .
[9] M Gumbleton,et al. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. , 2001, Journal of pharmaceutical sciences.
[10] T. Vanderah,et al. Neuropathic pain: the paradox of dynorphin. , 2001, Molecular interventions.
[11] P. Knapp,et al. Structure–Activity Analysis of Dynorphin A Toxicity in Spinal Cord Neurons: Intrinsic Neurotoxicity of Dynorphin A and Its Carboxyl-Terminal, Nonopioid Metabolites , 2001, Experimental Neurology.
[12] B. Chait,et al. Differential biotransformation of dynorphin A(1–17) and dynorphin A(1–13) peptides in human blood, ex vivo , 1996, Peptides.
[13] B. Chait,et al. In vitro biotransformation of dynorphin A (1-17) is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption/ionization mass spectrometry. , 1996, The Journal of pharmacology and experimental therapeutics.
[14] K. Audus,et al. Leucine enkephalin effects on paracellular and transcellular permeation pathways across brain microvessel endothelial cell monolayers. , 1994, Journal of cardiovascular pharmacology.
[15] K. Audus,et al. Leucine Enkephalin Effects on Brain Microvessel Endothelial Cell Monolayer Permeability , 1994, Pharmaceutical Research.
[16] R. Oishi,et al. Enhancement of blood-brain barrier permeability to sodium fluorescein by stimulation of µ opioid receptors in mice , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.
[17] W. Banks,et al. Analgesia and the blood-brain barrier transport system for Tyr-MIF-1/enkephalins: Evidence for a dissociation , 1988, Neuropharmacology.
[18] W. Banks,et al. Tyr-MIF-1 and Met-enkephalin share a saturable blood-brain barrier transport system , 1987, Peptides.
[19] W. Banks,et al. Carrier-mediated transport of enkephalins and N-Tyr-MIF-1 across blood-brain barrier. , 1986, The American journal of physiology.
[20] K. Audus,et al. Characterization of an In Vitro Blood–Brain Barrier Model System for Studying Drug Transport and Metabolism , 1986, Pharmaceutical Research.
[21] E. Hall,et al. Pathobiology of dynorphins in trauma and disease. , 2005, Frontiers in bioscience : a journal and virtual library.